469 related articles for article (PubMed ID: 28814275)
1. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
2. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
[TBL] [Abstract][Full Text] [Related]
3. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
5. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
7. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Kim SY; Hong YS; Kim BC; Park JW; Choi HS; Jeong SY; Kim DY; Hong CW; Sohn DK; Jung KH
Invest New Drugs; 2009 Jun; 27(3):269-74. PubMed ID: 18815728
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
[TBL] [Abstract][Full Text] [Related]
13. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY; S Hong Y; K Shim E; Kong SY; Shin A; Baek JY; Jung KH
Br J Cancer; 2013 Sep; 109(6):1420-7. PubMed ID: 23963147
[TBL] [Abstract][Full Text] [Related]
14. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.
Takaoka T; Kimura T; Shimoyama R; Kawamoto S; Sakamoto K; Goda F; Miyamoto H; Negoro Y; Tsuji A; Yoshizaki K; Goji T; Kitamura S; Yano H; Okamoto K; Kimura M; Okahisa T; Muguruma N; Niitsu Y; Takayama T
Cancer Chemother Pharmacol; 2016 Aug; 78(2):397-403. PubMed ID: 27342247
[TBL] [Abstract][Full Text] [Related]
16. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of S-1 in colorectal cancer.
Miyamoto Y; Sakamoto Y; Yoshida N; Baba H
Expert Opin Pharmacother; 2014 Aug; 15(12):1761-70. PubMed ID: 25032886
[TBL] [Abstract][Full Text] [Related]
19. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
20. Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.
Lee DJ; Lee J; Lee HY; Lim T; Lee SJ; Yi SY; Park SH; Park JO; Lim HY; Kang WK; Park YS
Med Oncol; 2011 Dec; 28 Suppl 1():S291-4. PubMed ID: 21116875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
